A common gastrointestinal cancer drug that crosses the blood-brain barrier showed promise in patients with aggressive ...

Apr. 10, 2025 — Research on the biological basis of addiction has found that the critical epigenetic enzyme histone deacetylase 5 (HDAC5) limits the expression of the gene Scn4b, regulating ...

That helped with the symptoms but started causing severe side effects. Looking for a solution, Smith decided to participate in a Stanford University clinical trial for a drug called Avapritinib, or ...

A study is recruiting patients with systemic mastocytosis (SM) with an associated hematologic neoplasm (SM-AHN) to evaluate the safety and tolerability of combination therapy with avapritinib and ...

The Company delivers its approved medicines in the US and Europe, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST. Analyst Michael Yee from Jefferies maintained a Buy rating ...

有希望的早期临床数据 最后，在小鼠模型中进行了额外的测试后，研究人员通过一项富有同情心的使用计划，用avapritinib治疗了8名患有高度胶质瘤的儿童和年轻成人患者。大多数患者有dmg， 8人中有7人有PDGFRA改变。所有患者之前都接受过手术活检或切除和放疗 ...

Our group was the first, for example, to apply LIFU for opening the blood-brain barrier and delivering drugs for the treatment of Diffuse Intrinsic Pontine Gliomas, a rare type of brain tumor that ...

- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. - China: Approved for first-line treatment of ...

- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab ...

Next, the team tested the activity of four PDGFRA inhibitors (dasatinib, crenolanib, axitinib, and avapritinib) against a panel of glioma cell lines with PDGFRA alterations. Of these drugs, ...